| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 55 kDa actin bundling protein; Actin bundling protein; FAN1; Fascin 1; Fascin; Singed (Drosophila) like (sea urchin fascin homolog like); Fascin homolog 1; Fascin |
| Entrez GeneID | 6624 |
| WB Predicted band size | Calculated MW: 55 kDa; Observed MW: 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Monkey |
| Immunogen | Recombinant protein of human Fascin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Fascin抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Fascin overexpression promotes cell motility and mediates tumor metastasis in breast cancer"*
**作者**: Hashimoto Y et al.
**摘要**: 该研究通过免疫组化分析乳腺癌组织，发现Fascin蛋白的高表达与肿瘤转移和患者不良预后显著相关。实验表明，Fascin抗体通过增强肌动蛋白束形成，促进癌细胞迁移和侵袭能力，提示其作为乳腺癌转移的生物标志物和治疗靶点。
---
2. **文献名称**: *"Fascin-1 monoclonal antibody inhibits tumor metastasis by suppressing filopodia formation in colorectal cancer"*
**作者**: Lin S et al.
**摘要**: 研究团队开发了一种特异性靶向Fascin-1的单克隆抗体，通过体外实验和小鼠模型证明其能有效抑制结直肠癌细胞的丝状伪足形成和转移。Western blot和免疫荧光证实该抗体通过阻断Fascin与β-catenin的相互作用抑制侵袭性表型。
---
3. **文献名称**: *"Fascin as a novel diagnostic marker for aggressive thyroid carcinoma"*
**作者**: Dickson BC et al.
**摘要**: 研究利用Fascin抗体对甲状腺癌临床样本进行染色，发现Fascin在低分化癌和未分化癌中表达显著升高，而在良性病变中几乎不表达。结果表明，Fascin可作为区分甲状腺癌侵袭性亚型的关键诊断标志物。
---
以上文献聚焦于Fascin抗体在肿瘤转移机制、治疗干预及临床诊断中的应用，涵盖乳腺癌、结直肠癌和甲状腺癌等研究模型。
Fascin antibodies are immunological tools used to detect and study fascin, a 55-58 kDa actin-binding protein critical in regulating cytoskeletal dynamics. Fascin (also known as Fascin-1 or p55) is primarily involved in bundling filamentous actin (F-actin) to form parallel arrays, which stabilize cellular protrusions like filopodia and invadopodia. These structures are essential for cell migration, adhesion, and invasion, implicating fascin in processes such as embryonic development, immune response, and cancer metastasis.
In normal tissues, fascin expression is generally low but becomes significantly upregulated in various cancers, including colorectal, breast, and pancreatic carcinomas. Overexpression correlates with aggressive tumor behavior, poor prognosis, and metastatic potential. Fascin antibodies are thus widely utilized in research to assess fascin levels via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They help identify fascin's role as a potential biomarker for cancer progression or a therapeutic target.
Commercial fascin antibodies are available from multiple suppliers (e.g., Abcam, Cell Signaling Technology) and are often validated for specificity using knockout cell lines. Some studies explore targeting fascin with inhibitory antibodies or small molecules to suppress metastasis, though therapeutic applications remain experimental. Researchers must verify antibody clones (e.g., D8A5. 55K-2) for cross-reactivity, as fascin has homologs (Fascin-2. -3) with tissue-specific expression. Overall, fascin antibodies remain vital for elucidating cytoskeletal mechanisms in health and disease.
×
